NCT06011304招募中3 期
A Phase III, Open-Label, Multi-center Clinical Study to Assess the Diagnostic Performance and Safety of 18F-Florastamin PET/CT Imaging in Patients With at Least Intermediate Risk Prostate Cancer
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 入组人数
- 267
- 试验地点
- 1
- 主要终点
- Specificity
研究概览
简要总结
In this study, 18F-Florastamin PET/CT will be performed in patients with at least intermediate risk prostate cancer, to assess the diagnostic performance and safety of 18F-Florastamin PET/CT imaging.
This study will first carry out the pilot study (including pharmacokinetics and radiation dosimetry).
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Diagnostic
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Subjects fully understood the content, process, and potential risks of the study and voluntarily signed an informed consent form (ICF).
- •Male subjects aged 18 or older.
- •Subjects with histopathological diagnosis of prostate adenocarcinoma.
- •According to clinical judgment, radical prostatectomy and pelvic lymph node dissection (which can include patients with localized, regional lymph node metastasis or oligometastatic prostate cancer) are planned, and there is no surgical contraindication.
- •If it is localized prostate cancer, according to the Prostate Cancer Diagnosis and Treatment Guidelines of 2021 Chinese Society of Clinical Oncology, it is necessary to meet any of the following criteria:
- •Intermediate Risk: Has at least one intermediate risk factor: T2b-T2c; Gleason pattern 2 or 3; PSA 10-20 ng/mL, and does not include feature of high-risk or very-high-risk groups.
- •High Risk: Has no very-high-risk features and has at least one high-risk feature: T3a; Gleason Grade Group 4 or 5; PSA >20 ng/mL.
- •Very High Risk: Has at least one of the following: T3b-T4; Primary Gleason pattern 5; More than 4 punctures with Gleason Grade Group 4 or
- •ECOG score 0 or
- •Subjects who meet the following conditions in hematology, renal function, and liver function:
- •Platelet count>100 * 10^9/L
- •Urea nitrogen and creatinine<1.5 times upper limits of normal
- •AST and ALT<2.5 times upper limits of normal.
- •Expected survival time ≥ 6 months.
- •Subjects and their partners must use effective contraceptive measurements and avoid sperm donation from the date of signing ICF to 3 months after administration.
排除标准
- •Subjects who have participated in other interventional clinical trials before signing ICF and were within the 5 half-lives of the investigational drug, or who are currently participating in other interventional clinical trials or have participated in clinical trials of radioactive drugs within 1 year before signing ICF and have been discontinued for less than 3 months until the signing date of ICF.
- •Intravenous injection of iodinated contrast medium within 24 hours, or any high-density oral contrast medium (Such as barium sulfate. Oral water contrast is acceptable, such as compound meglumine diatrizoate oral liquid) within 5 days, prior to study drug administration.
- •Subjects administered any high energy (>300 KeV) gamma-emitting radioisotope within five physical half-lives prior to study drug administration.
- •Patients with prior androgen deprivation therapy or any other neoadjuvant agent.
- •The investigator determines that there are any medical diseases or other conditions that affect the safety or compliance of the subjects.
研究组 & 干预措施
18F-Florastamin Injection
Experimental
干预措施: [18F]Florastamin Injection (Drug)
结局指标
主要结局
Specificity
时间窗: Within 28 days following 18F-Florastamin PET/CT
The specificity of 18F-Florastamin PET/CT in patients with negative pelvic lymph node metastasis compared with the histopathology. The subjects underwent RP (radical prostatectomy) with PLND (pelvic lymph node dissection) within 28 days after the administration of 18F-Florastamin Injection. The histopathology results of the pelvic lymph node tissue collected from the subjects will be used as the standard of truth for this study.
次要结局
- Sensitivity(Within 28 days following 18F-Florastamin PET/CT)
研究者
研究点 (1)
Loading locations...
相似试验
招募中
3 期
Study of 18F-Florastamin PET/CT Imaging in Patients With Suspected Recurrence of Prostate CancerProstate CancerNCT06754085HTA Co., Ltd.131
已完成
3 期
Fluciclovine (18F) PET/CT in biochemicAL reCurrence Of Prostate caNcerCancer of the ProstateNCT02578940Blue Earth Diagnostics104
进行中（未招募）
不适用
Phase III prospective clinical trial: 18F-FCH/PET evaluation in early diagnosis of disease recurrence in prostate cancer - FCH_PETEUCTR2009-011189-27-ITISTITUTI FISIOTERAPICI OSPITALIERI
已完成
3 期
Study of 18F-DCFPyL PET/CT Imaging in Patients With Suspected Recurrence of Prostate CancerProstate AdenocarcinomaProstate Cancer RecurrentProstate Cancer MetastaticProstate CancerNCT03739684Progenics Pharmaceuticals, Inc.208
终止
1 期
[18F]FLOR (FC303) PET/CT Imaging in Patients With Prostate CancerMetastatic Prostate CancerNCT04528199Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins8